Related content

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies

By Bilenker Joshua   Stevenson James   Flaherty Keith   Algazy Kenneth   McLaughlin Kathy   Haller Daniel   Giantonio Bruce   Koehler M.   Garcia-Vargas J.   O’Dwyer Peter  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 4, 2004-04 ,pp. : 357-360

Springer Publishing Company

Access to resources Recommend Favorite

A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies

By Schaar Dale   Goodell Lauri   Aisner Joseph   Cui Xiao   Han Zheng   Chang Richard   Martin John   Grospe Stephanie   Dudek Liesel   Riley Joan   Manago Jacqueline   Lin Yong   Rubin Eric   Conney Allan   Strair Roger  

Cancer Chemotherapy and Pharmacology, Vol. 57, Iss. 6, 2006-06 ,pp. : 789-795

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer

By Campos Susana   Berlin Suzanne   Parker Leroy   Chen Wendy   Bunnell Craig   Atkinson Tina   Lee Julie   Matulonis Ursula   Hirsch Michelle   Harris Lyndsay   Krasner Carolyn  

International Journal of Clinical Oncology, Vol. 15, Iss. 4, 2010-08 ,pp. : 390-398

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

By Bruce Justine   Kolesar Jill   Hammers Hans   Stein Mark   Carmichael Lakeesha   Eickhoff Jens   Johnston Susan   Binger Kimberly   Heideman Jennifer   Perlman Scott   Jeraj Robert   Liu Glenn  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 485-493

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

By Mita M. M.   Poplin E.   Britten C. D.   Tap W. D.   Rubin E. H.   Scott B. B.   Berk L.   Rivera V. M.   Loewy J. W.   Dodion P.   Haluska F.   Sarantopoulos J.   Mita A.   Tolcher A.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1104-1111

Oxford University Press

Access to resources Recommend Favorite